Brii Bio acquires Vir’s antibody rights for Hepatitis B in Greater China
The development adds further growth to Brii Bio’s clinical pipeline of therapeutic candidates for HBV.

The development adds further growth to Brii Bio’s clinical pipeline of therapeutic candidates for HBV.
In June this year, Sierra filed a New Drug Application with the US Food and Drug Administration for momelotinib.
According to the new deal, AstraZeneca will have access to Covid-19 vaccine manufacturing at Oxford Biomedica’s Oxbox facility.
At the closing of the deal, Blueprint will get a total of $575m in cash.
Under the deal, Twist will receive upfront, milestone and royalty payments as well as annual maintenance fees.
Following the acquisition, Amgen Turkey will maintain its operations and serve its patients in the region.
The alliance will use Terumo and GenCure’s capabilities to set up a reference manufacturing centre for BioBridge Global.
Sutro could be eligible for milestone payments of up to $422.5m for each product candidate.
Thank you for subscribing to Pharmaceutical Technology